Dig Dis Sci: Hydroxysteroid 17-β Dehydrogenase 6 (HSD17 beta 6) is an immuno-immersion-related prognostic biomarker for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common deadly cancers in the world, with about 700,000 people dying each year worldwide.
Despite improvements in surgical techniques, the emergence of chemotherapy and targeted therapies over the past decade, the survival rate of liver cancer patients has improved, but the prognosis of liver cancer patients is still not satisfactory.
recurrence and metastasis are the main causes of poor prognostication in patients.
, in order to improve the prognosis of liver cancer, it is urgent to study the new molecular mechanism of recurrence and metastasis of liver cancer.
Tumor-immersed lymphocytes are heterogeneic lymphocytes in the tumor microenvironment (TME) and are involved in anti-tumor immune responses, including T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cells, macrophages and degeneration cells (DC).
, the interaction between tumor tissue and the immune system usually has a two-way effect.
For example, the immune system can identify and kill tumors with certainty, while tumor cells can form immunosuppressive micro-environments by expressing inhibitory molecules and surface secretion of tumor-related cytokines, thereby mediaing the body's immune tolerance to tumors, leading to immune escape.
, it is of great scientific significance to look for new liver cancer markers and their interaction mechanisms with immune cells.
study, the researchers examined the expression of HSD17B6 and its relationship to clinical prognosticity in HCC patients.
first performed weighted gene co-expression network analysis and protein-protein interaction analysis to identify important potential prognosted genes.
expression of all genes in liver cancer has been confirmed by the GEPIA, Oncomine, UALCAN and HPA databases.
, a survival analysis of the central gene was performed using the Kaplan-Meier plotter database.
, the correlation between hub genes and immune factors in HCC was studied through the GSEA, TIMER and TISIDB databases.
the expression of HSD17B6 in HSD is significantly lower than that of normal tissue.
expression of HSD17B6 was associated with poor overall survival and progressity-free survival in HCC patients, especially during the secondary disease stage (Phases II and III or III).
HSD17B6 is closely related to tumor-soaked B-cells, CD4-plus and CD8-T cells, macrophages, neophils, and degenerative cells.
changes in soytic cell copies may be the main reason for the negative correlation between HSD17B6 expression and immuno-immersion.
expression of HSD17B6 in HCC was negatively associated with the expression of several immune cell markers, including tired T-cell markers PD-1 and CTLA-4, indicating its role in regulating tumor immunity.
study found that the expression of HSD17B6 in HCC patients was significantly lower than in normal patients.
low expression of HSD17B6 was associated with poor overall survival and progressed survival rates in HCC patients, especially during the secondary disease stage (levels II and III).
HSD17B6 is closely related to the number of tumor-immersed B-cells, CD4-plus and CD8-T cells, macrophages, neophilic granulocytes, and degenerative cells.
changes in soytic cell copies may be the main reason for the negative correlation between HSD17B6 expression and immuno-immersion.
expression of HSD17B6 in HCC was negatively associated with the expression of several immune cell markers, including inert T-cell markers PD-1 and CTLA-4.
HSD17B6 is a separate potential prognostic biomarker of HCC that can be used to assess the level of immunocellular immersion in tumor tissue.
relatively low levels of HSD17B6 in HCC tissue may indicate a higher risk of tumor recurrence after treatment, so such patients will need intensive medical supervision.